7 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 18%
A multi-day slide in the biotech’s stock prompts a closer look at the numbers behind the momentum.
A seven-day slide in Arrowhead Pharmaceuticals (ARWR) has erased about $2.2 billion from the company’s market value. The stock has now moved lower for 7 consecutive trading days, a cumulative loss of 17.9%.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
ARWR Versus The S&P 500, Streak And Beyond
Here is how ARWR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | ARWR | S&P 500 |
|---|---|---|
| 1D | -0.6% | -0.5% |
| 7D (Current Streak) | -17.9% | 0.4% |
| 1M (21D) | -7.5% | -0.3% |
| 3M (63D) | 0.6% | 7.3% |
| YTD 2026 | 7.5% | 10.1% |
| 2025 | 253.1% | 16.4% |
| 2024 | -38.6% | 23.3% |
| 2023 | -24.6% | 24.2% |
The selling streak highlights a disconnect between growth and profitability.
This move is specific to the company; over the same 7 trading days the S&P 500 returned +0.4%. While the company’s 3-year average annual revenue growth is 454.7%, profitability metrics show significant strain. Its operating margin over the last twelve months is -35.7%, compared to an S&P 500 median of 18.4%.
The stock’s price-to-earnings multiple is -33.8, while the median for the index is 24.5. Such losing streaks are not especially common in the current market, where 18 S&P 500 stocks are on losing streaks of 3 days or more, versus 53 on winning streaks.
A streak is a signal to re-evaluate, not a command to act.
A streak of this length is primarily information. It signals that the market’s attention is focused and momentum has taken hold, but it does not provide a clear instruction to buy or sell. The disciplined response is to weigh the price action against the business fundamentals.
The data shows a company with very strong long-term returns, as the stock has returned +304.8% over the trailing twelve months. But it also shows a business whose current profitability metrics differ sharply from the market median, a contrast this recent selling may be weighing.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather own the whole group than one company’s story, a biotech ETF like XBI owns the whole group. That way, no single company’s next surprise decides the outcome.
ARWR Has Fallen 88% From A Peak Before As Well
A stock that falls day after day is a live lesson in what single-name exposure feels like. ARWR itself has fallen 88% from a peak within the past five years, and a fall like that lands very differently when one position carries too much of your wealth. Knowing what a repeat would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.